TW550087B - Solubilized sertraline compositions - Google Patents

Solubilized sertraline compositions Download PDF

Info

Publication number
TW550087B
TW550087B TW087110267A TW87110267A TW550087B TW 550087 B TW550087 B TW 550087B TW 087110267 A TW087110267 A TW 087110267A TW 87110267 A TW87110267 A TW 87110267A TW 550087 B TW550087 B TW 550087B
Authority
TW
Taiwan
Prior art keywords
acid
solubilizer
composition
patent application
scope
Prior art date
Application number
TW087110267A
Other languages
English (en)
Chinese (zh)
Inventor
Dwayne Thomas Friesen
Scott Max Herbig
Ravi Mysore Shanker
James Blair West
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21971159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW550087(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of TW550087B publication Critical patent/TW550087B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW087110267A 1997-07-01 1998-06-25 Solubilized sertraline compositions TW550087B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5141397P 1997-07-01 1997-07-01

Publications (1)

Publication Number Publication Date
TW550087B true TW550087B (en) 2003-09-01

Family

ID=21971159

Family Applications (1)

Application Number Title Priority Date Filing Date
TW087110267A TW550087B (en) 1997-07-01 1998-06-25 Solubilized sertraline compositions

Country Status (34)

Country Link
EP (1) EP0999829A1 (is)
JP (1) JP2000514100A (is)
KR (1) KR100366373B1 (is)
CN (1) CN1261794A (is)
AP (1) AP1192A (is)
AR (3) AR015917A1 (is)
AU (1) AU742535B2 (is)
BG (1) BG103918A (is)
BR (1) BR9810739A (is)
CA (1) CA2290974C (is)
CO (1) CO4940495A1 (is)
DZ (1) DZ2548A1 (is)
EA (1) EA002481B1 (is)
HN (1) HN1998000102A (is)
HR (1) HRP980377A2 (is)
HU (1) HUP0002236A3 (is)
ID (1) ID23429A (is)
IL (1) IL133076A (is)
IS (1) IS5260A (is)
MA (1) MA24587A1 (is)
NO (1) NO996520L (is)
OA (1) OA11243A (is)
PA (1) PA8454301A1 (is)
PE (1) PE97199A1 (is)
PL (1) PL337804A1 (is)
SK (1) SK181099A3 (is)
TN (1) TNSN98124A1 (is)
TR (1) TR199903297T2 (is)
TW (1) TW550087B (is)
UA (1) UA67741C2 (is)
UY (1) UY25071A1 (is)
WO (1) WO1999001120A1 (is)
YU (1) YU68299A (is)
ZA (1) ZA985708B (is)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20053427B (en) 1999-12-23 2005-01-25 Pfizer Prod Inc Pharmaceutical Compositions Providing Enhanced Drug Concentrations
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
AP2001002264A0 (en) 2000-08-30 2001-09-30 Pfizer Prod Inc Sustained release formulations for growth hormone secretagogues.
US20040191207A1 (en) * 2003-03-31 2004-09-30 Lipari John M. Alpha-hydroxy acid ester drug delivery compositions and methods of use
ES2439582T3 (es) * 2007-03-12 2014-01-23 Dsm Ip Assets B.V. Composiciones cosméticas
DK2468281T3 (en) 2009-08-19 2016-03-21 Eisai R&D Man Co Ltd Quinolinderivatholdig pharmaceutical composition
JPWO2011081117A1 (ja) * 2009-12-29 2013-05-09 興和株式会社 経口投与用固形医薬組成物
KR20120116422A (ko) * 2009-12-29 2012-10-22 코와 가부시키가이샤 경구 투여용 의약 조성물
CN109908354A (zh) * 2017-12-12 2019-06-21 万特制药(海南)有限公司 盐酸舍曲林口服浓缩液及其制备工艺
CN114894736B (zh) * 2022-05-20 2025-03-21 中化地质矿山总局地质研究院 一种氯化物型卤水中硝酸根的测定方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
ATE96999T1 (de) * 1989-08-30 1993-11-15 Pfizer Verwendung von sertralin zur behandlung von abhaengigkeiten von chemischen stoffen.
ZA97976B (en) * 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.

Also Published As

Publication number Publication date
PA8454301A1 (es) 2000-09-29
IL133076A0 (en) 2001-03-19
ZA985708B (en) 2000-01-10
AU7544898A (en) 1999-01-25
SK181099A3 (en) 2000-07-11
DZ2548A1 (fr) 2003-02-08
PE97199A1 (es) 1999-10-05
BG103918A (en) 2000-07-31
WO1999001120A1 (en) 1999-01-14
AR040279A2 (es) 2005-03-23
AP9801280A0 (en) 1998-06-30
KR20010013365A (ko) 2001-02-26
AU742535B2 (en) 2002-01-03
YU68299A (sh) 2002-06-19
CA2290974C (en) 2004-04-27
NO996520L (no) 2000-02-29
HUP0002236A3 (en) 2003-12-29
KR100366373B1 (ko) 2003-01-14
UY25071A1 (es) 2000-12-29
IL133076A (en) 2003-12-10
OA11243A (en) 2003-07-24
CA2290974A1 (en) 1999-01-14
TR199903297T2 (xx) 2000-07-21
IS5260A (is) 1999-11-19
BR9810739A (pt) 2000-09-12
MA24587A1 (fr) 1998-12-31
HRP980377A2 (en) 1999-04-30
CO4940495A1 (es) 2000-07-24
AR015917A1 (es) 2001-05-30
UA67741C2 (uk) 2004-07-15
HUP0002236A2 (hu) 2003-08-28
CN1261794A (zh) 2000-08-02
AR040280A2 (es) 2005-03-23
EP0999829A1 (en) 2000-05-17
NO996520D0 (no) 1999-12-28
HN1998000102A (es) 1999-01-08
PL337804A1 (en) 2000-09-11
ID23429A (id) 2000-04-20
TNSN98124A1 (fr) 2005-03-15
EA002481B1 (ru) 2002-06-27
JP2000514100A (ja) 2000-10-24
EA199900962A1 (ru) 2000-08-28
AP1192A (en) 2003-07-23

Similar Documents

Publication Publication Date Title
JP6209237B2 (ja) 酸不安定性薬物の液体剤形
KR101763700B1 (ko) 염료의 경구 투여를 위한 고체 조성물 및 이의 진단 용도
TW550087B (en) Solubilized sertraline compositions
Shashank et al. Approaches to increase the gastric residence time: floating drug delivery systems-a review
JP2000515871A (ja) トラマドール複式ユニット製剤
JP2018193401A5 (is)
JP2002080398A (ja) ｐＨに依存する多相的な放出を伴う経口用の固体の薬学的組成物
US20110244034A1 (en) Sustained release drug delivery system
CN110381925A (zh) 间苯三酚和三甲基间苯三酚的药物制剂
US20160317609A1 (en) Formulations comprising cyclosporin a
CN108348475A (zh) 处于液体剂型的多层药学活性化合物释放微粒
JPS61500849A (ja) 造影剤およびその使用方法
CN107106644A (zh) 包含环孢菌素的组合物
CN101827584A (zh) N-芳基脲基药物的固态分散体产品
FI78615C (fi) Foerfarande foer framstaellning av ett komplex av karragenan och anvaendningen av karragenan som komplexbildande medel foer emepron.
CN114288274A (zh) 一种西甲硅油干混乳剂及其制备方法和应用
CN110772647B (zh) 一种包载含碘造影用药物的胶囊及其制备方法
Sanghavi et al. Gastroretentive drug delivery system: An overview
JP4629730B2 (ja) 薬物ののみ易さを改善するための医薬組成物及びその調製方法
US20220218699A1 (en) New Pharmaceutical Formulation
BE839625A (fr) Procede pour l'enrobage enterique de medicaments ainsi enrobes
Patel et al. Floating microspheres encapsulating carvedilol for the effective management of hypertension
FR3109089A1 (fr) Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales
Panda et al. Quality by Design Enabled Formulation Optimization of Rabeprazole Sodium Mucoadhesive Microcapsules for the Treatment of Gastroesophageal Reflux Disease
WO2005032588A1 (ja) 塩基性薬剤含有製剤

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent